Novel epigenetic cancer drugs
| Reference number | |
| Coordinator | Beactica AB |
| Funding from Vinnova | SEK 3 031 547 |
| Project duration | November 2014 - February 2016 |
| Status | Completed |
Purpose and goal
The project has optimized several series of small molecular compounds in lead generation, modulating epigenetic target proteins with relevance for cancer and Alzheimer´s disease.
Results and expected effects
The project results have clear commercial value, and are expected to lead to a licence agreement. With availability of continued resources to show progress during negotiations, the deal is expected to lead to considerable growth of Beactica, with new employments and increased turnover/profit.
Approach and implementation
The research has been distributed in an international network of highly qualified CROs and academic collaborators. This has enabled a dynamic use of resources and expertise in the wide range of research fields that are required to achieve commercially viable results in drug discovery.